NASDAQ:SWAV Shockwave Medical Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Shockwave Medical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $72.34 +1.64 (+2.32 %) (As of 09/18/2020 04:30 PM ET) Add Compare Share Today's Range$71.10Now: $72.34▼$73.8150-Day Range$49.26MA: $58.21▼$70.6552-Week Range$22.01Now: $72.34▼$73.81Volume1.91 million shsAverage Volume464,043 shsMarket Capitalization$2.46 billionP/E RatioN/ADividend YieldN/ABeta0.98 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingShockwave Medical has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.71, Shockwave Medical has a forecasted downside of 23.0% from its current price of $72.32.Amount of Analyst CoverageShockwave Medical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesShockwave Medical has received 83 “outperform” votes. (Add your “outperform” vote.)Underperform VotesShockwave Medical has received 95 “underperform” votes. (Add your “underperform” vote.)Community SentimentShockwave Medical has received 53.37% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Shockwave Medical and other stocks. Vote “Outperform” if you believe SWAV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SWAV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldShockwave Medical does not currently pay a dividend.Dividend GrowthShockwave Medical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Shockwave Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,884,900.00 in company stock.Percentage Held by InsidersOnly 15.30% of the stock of Shockwave Medical is held by insiders.Percentage Held by Institutions83.75% of the stock of Shockwave Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Shockwave Medical are expected to grow in the coming year, from ($2.20) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shockwave Medical is -34.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Shockwave Medical is -34.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioShockwave Medical has a P/B Ratio of 10.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.26 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SWAV Previous Symbol CUSIPN/A CIKN/A Webwww.shockwavemedical.com Phone510-279-4262Debt Debt-to-Equity Ratio0.10 Current Ratio14.90 Quick Ratio13.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.93 million Price / Sales57.30 Cash FlowN/A Price / Cash FlowN/A Book Value$6.81 per share Price / Book10.62Profitability EPS (Most Recent Fiscal Year)($2.14) Net Income$-51,110,000.00 Net Margins-126.34% Return on Equity-35.68% Return on Assets-29.43%Miscellaneous Employees162 Outstanding Shares34,003,000Market Cap$2.46 billion Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $72.34 +1.64 (+2.32 %) (As of 09/18/2020 04:30 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SWAV News and Ratings via Email Sign-up to receive the latest news and ratings for SWAV and its competitors with MarketBeat's FREE daily newsletter. Shockwave Medical (NASDAQ:SWAV) Frequently Asked Questions How has Shockwave Medical's stock been impacted by COVID-19 (Coronavirus)? Shockwave Medical's stock was trading at $34.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SWAV shares have increased by 110.0% and is now trading at $72.32. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Shockwave Medical? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Shockwave Medical. When is Shockwave Medical's next earnings date? Shockwave Medical is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Shockwave Medical. How were Shockwave Medical's earnings last quarter? Shockwave Medical Inc (NASDAQ:SWAV) announced its earnings results on Tuesday, August, 11th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.06. The company had revenue of $10.30 million for the quarter, compared to the consensus estimate of $8.35 million. Shockwave Medical had a negative net margin of 126.34% and a negative return on equity of 35.68%. Shockwave Medical's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.38) earnings per share. View Shockwave Medical's earnings history. What price target have analysts set for SWAV? 7 brokers have issued twelve-month price objectives for Shockwave Medical's shares. Their forecasts range from $23.00 to $80.00. On average, they anticipate Shockwave Medical's share price to reach $55.71 in the next twelve months. This suggests that the stock has a possible downside of 23.0%. View analysts' price targets for Shockwave Medical. Are investors shorting Shockwave Medical? Shockwave Medical saw a drop in short interest in the month of August. As of August 14th, there was short interest totaling 3,390,000 shares, a drop of 14.4% from the July 30th total of 3,960,000 shares. Based on an average daily trading volume, of 416,500 shares, the days-to-cover ratio is currently 8.1 days. Currently, 12.7% of the company's shares are short sold. View Shockwave Medical's Short Interest. Who are some of Shockwave Medical's key competitors? Some companies that are related to Shockwave Medical include Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Inari Medical (NARI), Inspire Medical Systems (INSP), NuVasive (NUVA), Inovio Pharmaceuticals (INO), Merit Medical Systems (MMSI) and Silk Road Medical (SILK). View all competitors. What other stocks do shareholders of Shockwave Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), salesforce.com (CRM), Trade Desk (TTD), Walt Disney (DIS), Square (SQ), Paypal (PYPL), Roku (ROKU), Alibaba Group (BABA), Shopify (SHOP) and Okta (OKTA). Who are Shockwave Medical's key executives? Shockwave Medical's management team includes the following people: Mr. Douglas E. Godshall, CEO, Pres & Director (Age 54)Mr. Daniel Puckett, CFO & Sec. (Age 55)Mr. Isaac Zacharias, Chief Commercial Officer (Age 44)Mr. Daniel Hawkins, Founder and Sr. Advisor (Age 52)Mr. John M. Adams, Co-Founder and Technical Advisor (Age 72) When did Shockwave Medical IPO? (SWAV) raised $75 million in an initial public offering (IPO) on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers. What is Shockwave Medical's stock symbol? Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV." Who are Shockwave Medical's major shareholders? Shockwave Medical's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.90%), Vanguard Group Inc. (6.29%), Gilder Gagnon Howe & Co. LLC (6.01%), Jennison Associates LLC (1.82%), Macquarie Group Ltd. (1.75%) and Bellevue Group AG (1.31%). Company insiders that own Shockwave Medical stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, James E Flynn and Sofinnova Capital Vii Fcpr. View institutional ownership trends for Shockwave Medical. Which institutional investors are selling Shockwave Medical stock? SWAV stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., California Public Employees Retirement System, Prudential Financial Inc., Cypress Capital Management LLC WY, US Bancorp DE, and Private Advisor Group LLC. Company insiders that have sold Shockwave Medical company stock in the last year include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, and Sofinnova Capital Vii Fcpr. View insider buying and selling activity for Shockwave Medical. Which institutional investors are buying Shockwave Medical stock? SWAV stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Gilder Gagnon Howe & Co. LLC, FMR LLC, Vanguard Group Inc., Point72 Asset Management L.P., Goldman Sachs Group Inc., Bellevue Group AG, and Rhenman & Partners Asset Management AB. View insider buying and selling activity for Shockwave Medical. How do I buy shares of Shockwave Medical? Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Shockwave Medical's stock price today? One share of SWAV stock can currently be purchased for approximately $72.32. How big of a company is Shockwave Medical? Shockwave Medical has a market capitalization of $2.46 billion and generates $42.93 million in revenue each year. The company earns $-51,110,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Shockwave Medical employs 162 workers across the globe. What is Shockwave Medical's official website? The official website for Shockwave Medical is www.shockwavemedical.com. How can I contact Shockwave Medical? Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at 510-279-4262 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
